Several pharmaceutical methods have been developed to treat Type 2 diabetes by focusing on the development of oral DPP-IV inhibitors to block the degradation of the incretin hormones GLP-1 and GIP [52]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.